Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials
Cutaneous lupus erythematosus (CLE) is an autoimmune skin condition associated with a considerable treatment burden and diminished quality of life. The absence of a consensus outcome measure to evaluate therapeutic response has posed a challenge to CLE drug development. The Cuta…